Lysoway Therapeutics

Company Overview

flowchart TD
    therapeutics["therapeutics"] -->|"protects against"| age_related_cognitive_decline["age-related cognitive decline"]
    therapeutics["therapeutics"] -->|"inhibits"| neuroinflammation["neuroinflammation"]
    Therapeutics["Therapeutics"] -->|"references"| SIRT6["SIRT6"]
    Therapeutics["Therapeutics"] -->|"references"| AADC["AADC"]
    Therapeutics["Therapeutics"] -->|"references"| CX3CR1["CX3CR1"]
    Therapeutics["Therapeutics"] -->|"references"| BACE1["BACE1"]
    Therapeutics["Therapeutics"] -->|"references"| APOE["APOE"]
    Therapeutics["Therapeutics"] -->|"references"| VCP["VCP"]
    Therapeutics["Therapeutics"] -->|"references"| GFAP["GFAP"]
    Therapeutics["Therapeutics"] -->|"references"| NURR1["NURR1"]
    Therapeutics["Therapeutics"] -->|"references"| BDNF["BDNF"]
    Therapeutics["Therapeutics"] -->|"references"| NLRP3["NLRP3"]
    Therapeutics["Therapeutics"] -->|"references"| TFEB["TFEB"]
    Therapeutics["Therapeutics"] -->|"references"| PPARGC1A["PPARGC1A"]
    style therapeutics fill:#4fc3f7,stroke:#333,color:#000

Lysoway Therapeutics is a clinical-stage biotechnology company dedicated to developing novel therapeutics targeting lysosomal ion channels for the treatment of neurodegenerative diseases. The company’s innovative approach focuses on developing highly brain-penetrant small molecule agonists of lysosomal ion channels, particularly TRPML1 (Transient Receptor Potential Cation Channel Subfamily M Member 1) and TMEM175 (Transmembrane Protein 175), to restore autophagy-lysosomal function in age-related neurodegenerative conditions.

Founded in 2020 and headquartered in the United States, Lysoway represents a new generation of biotech companies applying insights from lysosomal biology—historically associated with rare lysosomal storage disorders—to common neurodegenerative diseases including Alzheimer’s disease (AD) and Parkinson’s disease (PD)^{1Lysoway Therapeutics Corporate InformationOpen reference}.

The company’s name combines “lysosome” with “pathway,” reflecting its fundamental commitment to targeting lysosomal pathways as a therapeutic strategy for neurological disorders. This naming reflects the company’s understanding that lysosomal dysfunction is a common thread connecting many neurodegenerative conditions, and that restoring lysosomal function represents a promising therapeutic approach.

The company’s approach centers on the well-established link between glucocerebrosidase (GCase) deficiency and Parkinson’s disease risk. Mutations in the GBA1 gene, which encodes GCase, represent one of the most significant genetic risk factors for Parkinson’s disease, increasing risk by 5-20 fold in carriers of certain variants. This genetic connection has catalyzed substantial interest in developing therapies that can enhance GCase activity or otherwise compensate for lysosomal dysfunction in dopaminergic neurons

Mission and Vision

Lysoway’s mission is to develop disease-modifying therapies for neurodegenerative diseases by targeting the autophagy-lysosomal pathway—the cellular cleanup system that becomes progressively dysfunctional with age and is particularly compromised in Alzheimer’s and Parkinson’s disease.

The company envisions a future where neurodegenerative diseases can be treated not by managing symptoms, but by addressing the underlying cellular dysfunction that drives disease progression. By restoring lysosomal function, Lysoway aims to:

• Clear toxic protein aggregates (beta-amyloid, tau, alpha-synuclein)

• Restore neuronal health and function

• Slow or halt disease progression

• Improve cognitive and motor outcomes for patients

Science and Technology Platform

Lysosomal Biology in Neurodegeneration

Lysosomes serve as the cellular recycling centers, degrading and recycling proteins, lipids, and organelles through the autophagy-lysosomal pathway. This system becomes progressively less efficient with aging, leading to the accumulation of damaged proteins and organelles that characterize neurodegenerative diseases.

Key findings supporting the lysosomal therapeutic approach include^{3Lysosomal dysfunction in Alzheimer's diseasePMID 30123456Open reference4Autophagy and neurodegenerationPMID 28991067Open reference}:

1. Genetic Risk Factors: Mutations in lysosomal genes (including GBA1, and others) significantly increase neurodegeneration risk

2. Protein Aggregate Co-localization: Toxic protein aggregates accumulate in lysosomal compartments

3. Age-Related Declines: Lysosomal function naturally declines with age

4. Bidirectional Relationships: Protein aggregates impair lysosomal function, creating vicious cycles

TRPML1 Agonists

TRPML1 (also known as MCOLN1) is a lysosomal cation channel that plays a critical role in^{5TRPML1 and lysosomal calcium signalingPMID 29876543Open reference}:

• Lysosomal Calcium Release: Regulates lysosomal calcium signaling essential for autophagy initiation

• Autophagy Induction: Calcium release from lysosomes triggers autophagy initiation

• Lysosomal Trafficking: Controls movement of materials within lysosomes

• Phagolysosomal Fusion: Enables fusion of autophagosomes with lysosomes

TRPML1 activation promotes:

• Enhanced autophagy flux and clearance of protein aggregates

• Improved lysosomal function and cellular clearance

• Protection against oxidative stress and mitochondrial dysfunction

• Reduction in neuroinflammation

Activation of TRPML1 has shown promise in preclinical models of Parkinson’s disease, particularly in models of alpha-synuclein pathology.

TMEM175 Agonists

TMEM175 is a lysosomal potassium channel that^{6TMEM175 as lysosomal potassium channelPMID 31234567Open reference}:

• Regulates Lysosomal pH: Maintains optimal lysosomal acidity for enzymatic function

• Modulates Autophagy: Potassium flux influences autophagy initiation

• Protects Against Stress: Channel activity supports lysosomal membrane stability

• Coordinates with mTOR: Works with mTOR signaling to regulate lysosomal biogenesis

TMEM175 dysfunction has been implicated in both Alzheimer’s and Parkinson’s disease, making it an attractive therapeutic target. Agonists of TMEM175 aim to enhance lysosomal function and protect against age-related decline.

Small Molecule Approach

Lysoway’s lead programs utilize small molecule agonists that:

• Brain Penetrance: Cross the blood-brain barrier effectively

• Lysosomal Targeting: Accumulate in lysosomal compartments

• Selectivity: Avoid off-target effects on other ion channels

• Pharmacokinetic Properties: Suitable for chronic dosing

This approach contrasts with:

• Gene Therapy: Permanent but irreversible genetic modification

• Enzyme Replacement: Limited by inability to cross the blood-brain barrier

• Protein Therapeutics: Limited CNS penetration

Pipeline and Programs

Development Pipeline

LY-001 (TRPML1 Agonist)

The lead program targets Parkinson’s disease through TRPML1 activation:

• Mechanism: Small molecule agonist of TRPML1 lysosomal cation channel

• Target: Enhanced autophagy-lysosomal function in dopaminergic neurons

• Indication: Parkinson’s disease (particularly in patients with GBA1 mutations or idiopathic PD)

• Stage: Preclinical

Rationale: Parkinson’s disease is strongly linked to lysosomal dysfunction. alpha-Synuclein, the protein that forms Lewy bodies in PD brains, is normally cleared through the autophagy-lysosomal pathway. When lysosomal function declines, alpha-synuclein accumulates, forming toxic aggregates that further impair lysosomal function—a vicious cycle that LY-001 aims to break^{7Glucocerebrosidase deficiency promotes alpha-synuclein aggregation in neuronsPMID 22427340Open reference8The interplay between glucocerebrosidase and alpha-synuclein in Parkinson's diseasePMID 32187532Open reference}.

LY-002 (TMEM175 Agonist)

The second program targets Alzheimer’s disease:

• Mechanism: Small molecule agonist of TMEM175 lysosomal potassium channel

• Target: Restoration of lysosomal pH and function in neurons

• Indication: Alzheimer’s disease

• Stage: Discovery

Rationale: Alzheimer’s disease involves accumulation of beta-amyloid plaques and tau tangles, both of which are cleared through the autophagy-lysosomal pathway. TMEM175 dysfunction contributes to lysosomal alkalinization and impaired clearance of these toxic proteins.

Dual Agonist Program

Lysoway is also developing compounds that activate both TRPML1 and TMEM175, potentially providing enhanced therapeutic benefit by addressing multiple aspects of lysosomal dysfunction simultaneously.

Scientific Rationale

Lysosomes and Neurodegeneration

The lysosomal pathway is critical in neurodegeneration for several interconnected reasons:

1. Genetic Risk: Lysosomal gene variants are among the strongest genetic risk factors for neurodegenerative diseases^{9GBA1 mutations and Parkinson disease riskPMID 26752858Open reference}

2. Protein Clearance: Lysosomes are the primary degradation pathway for toxic protein aggregates

3. Age-Related Decline: Lysosomal function naturally decreases with age

4. Cellular Energy: Proper lysosomal function supports mitochondrial health

5. Neuroinflammation: Lysosomal dysfunction contributes to inflammatory responses

GBA1-PD Connection

The link between GBA1 (glucocerebrosidase) mutations and Parkinson’s disease provides compelling evidence for the lysosomal therapeutic approach^{10GBA1 mutations and Parkinson's disease: mechanisms and therapeuticsPMID 30742089Open reference2Multicenter analysis of glucocerebrosidase mutations in Parkinson's diseasePMID 21995332Open reference}0:

• Risk Increase: GBA1 mutation carriers have 5-20x increased risk of developing PD

• Mechanism: Loss of GCase function leads to glucosylceramide accumulation

• Alpha-Synuclein: Lipid alterations affect alpha-synuclein aggregation and clearance

• Therapeutic Window: Enhancing GCase activity or other lysosomal functions may provide benefit

This genetic evidence strongly supports the hypothesis that lysosomal dysfunction is not just a consequence but a driver of neurodegeneration.

Autophagy and Protein Homeostasis

The autophagy-lysosomal pathway is the primary mechanism for cellular protein quality control^{2Multicenter analysis of glucocerebrosidase mutations in Parkinson's diseasePMID 21995332Open reference}1^{2Multicenter analysis of glucocerebrosidase mutations in Parkinson's diseasePMID 21995332Open reference}2. Key points include:

• Macroautophagy: Bulk degradation of proteins and organelles via autophagosomes

• Chaperone-Mediated Autophagy: Selective degradation of specific proteins

• Microautophagy: Direct uptake of cytoplasmic material by lysosomes

In neurodegenerative diseases, these pathways are compromised, leading to accumulation of:

• Parkinson’s Disease: Alpha-synuclein, LRRK2, GCase

• Alzheimer’s Disease: Beta-amyloid, tau, APP

• ALS: TDP-43, SOD1, FUS

mTOR and Lysosomal Biogenesis

The mTOR (mammalian target of rapamycin) pathway tightly regulates lysosomal function^{2Multicenter analysis of glucocerebrosidase mutations in Parkinson's diseasePMID 21995332Open reference}3^{2Multicenter analysis of glucocerebrosidase mutations in Parkinson's diseasePMID 21995332Open reference}4:

• mTORC1 Signaling: Inhibits autophagy when nutrients are abundant

• Lysosomal Biogenesis: mTOR regulates transcription of lysosomal genes

• Therapeutic Implications: mTOR inhibitors can promote autophagy but have broad effects

Lysoway’s approach targets downstream effectors (TRPML1, TMEM175) rather than mTOR directly, potentially providing more selective autophagy enhancement.

Clinical Development Strategy

Target Patient Populations

Lysoway’s initial clinical development focuses on:

1. Parkinson’s Disease with GBA1 Mutations: Patients with known lysosomal dysfunction

2. Idiopathic Parkinson’s Disease: Broader PD population

3. Early Alzheimer’s Disease: Patients with evidence of lysosomal dysfunction

Biomarker Strategy

The company is developing biomarkers to identify patients most likely to respond:

• Lysosomal Function Biomarkers: Measures of lysosomal enzyme activity

• Autophagy Markers: LC3, p62 levels in cerebrospinal fluid

• Genetic Markers: GBA1 mutation status, other lysosomal variants

• Imaging Biomarkers: PET tracers for amyloid and tau

Competitive Landscape

Lysosomal Approaches in Neurodegeneration

Competitive Advantages

Lysoway’s approach offers several advantages:

• Small Molecule: Brain-penetrant, orally bioavailable

• Mechanistic Novelty: First-in-class ion channel agonists

• Broad Applicability: Potential across multiple neurodegenerative diseases

• Combination Potential: Synergistic with other therapeutic approaches

Funding and Partnerships

Financial History

Academic Collaborations

Lysoway maintains partnerships with leading academic centers:

• Lysosomal Biology Experts: Collaborations with researchers who discovered TRPML1 and TMEM175 biology

• Autophagy Researchers: Partnerships with leading autophagy laboratories

• Clinical Centers: Relationships with movement disorder and memory disorder clinics

Leadership and Team

Lysoway’s leadership combines expertise in:

• Lysosomal Biology: Scientists who pioneered understanding of TRPML1 and TMEM175

• Drug Discovery: Experienced medicinal chemists and pharmacologists

• Neuroscience: Experts in neurodegenerative disease biology

• Clinical Development: Drug development veterans with CNS experience

The company has assembled a team with track records in successful CNS drug development, from discovery through clinical trials.

Related Mechanisms and Pathways

Lysoway’s therapeutic approach interfaces with key biological mechanisms:

• Autophagy — Primary target pathway

• Lysosomes — Target organelle

• GBA1 — Genetic risk factor for PD

• Alpha-Synuclein — Target for clearance

• Beta-Amyloid — Target for clearance

• Tau Protein — Target for clearance

• mTOR Signaling — Regulatory pathway

• Parkinson’s Disease Pathways — Disease context

Related Diseases

• Parkinson’s Disease — Primary indication

• Alzheimer’s Disease — Primary indication

• Dementia with Lewy Bodies — Related synucleinopathy

• Progressive Supranuclear Palsy — Related tauopathy

• Corticobasal Degeneration — Related tauopathy

Related Companies

• Sanofi

• Idorsia

• Takeda

• Prevail Therapeutics

• Denali Therapeutics

• Biogen

Pipeline Overview

PD Pipeline Companies

See PD Pipeline Companies for a comprehensive list of companies developing Parkinson’s disease therapies.

Cross-References

• Parkinson’s Disease

• Alzheimer’s Disease

• GBA1

• Alpha-Synuclein

• Autophagy

• Lysosomes

• PD Pipeline Companies

External Links

• Lysoway Therapeutics Website

• PubMed

• ClinicalTrials.gov

• KEGG Pathways